| Segment Reporting |
10. Segment Reporting Our CODM manages our operations on an integrated basis for the purpose of allocating resources. When evaluating our financial performance, the CODM regularly reviews total revenues, total expenses, and research and development expenses by project and the CODM makes decisions using this information. The table below is a summary of the segment profit or loss, including significant expenses, in thousands:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
Nine Months Ended
September 30, |
|
|
2025 |
|
|
2024 |
|
2025 |
|
|
2024 |
|
Collaboration revenue |
$ |
20,750 |
|
|
$ |
— |
|
$ |
50,146 |
|
|
$ |
— |
|
Less: |
|
|
|
|
|
|
|
|
|
|
Ziftomenib-related costs |
|
40,320 |
|
|
|
18,993 |
|
|
107,851 |
|
|
|
52,335 |
|
Darlifarnib (KO-2806)-related costs |
|
8,494 |
|
|
|
5,178 |
|
|
19,871 |
|
|
|
13,026 |
|
Tipifarnib-related costs |
|
443 |
|
|
|
721 |
|
|
2,578 |
|
|
|
3,560 |
|
Discovery stage program-related costs |
|
1,744 |
|
|
|
1,769 |
|
|
5,323 |
|
|
|
4,950 |
|
Research and development personnel costs and other expenses |
|
13,695 |
|
|
|
11,474 |
|
|
41,790 |
|
|
|
32,611 |
|
Share-based compensation expense |
|
10,965 |
|
|
|
8,324 |
|
|
25,756 |
|
|
|
25,266 |
|
Other segment expenses(1) |
|
25,086 |
|
|
|
13,425 |
|
|
64,340 |
|
|
|
38,992 |
|
Total operating expenses |
|
100,747 |
|
|
|
59,884 |
|
|
267,509 |
|
|
|
170,740 |
|
Other income (expenses) |
|
|
|
|
|
|
|
|
|
|
Interest and other income |
|
6,274 |
|
|
|
5,892 |
|
|
21,088 |
|
|
|
17,190 |
|
Interest expense |
|
(393 |
) |
|
|
(412 |
) |
|
(1,166 |
) |
|
|
(1,216 |
) |
Income tax expense |
|
— |
|
|
|
— |
|
|
(226 |
) |
|
|
— |
|
Segment and net loss |
$ |
(74,116 |
) |
|
$ |
(54,404 |
) |
$ |
(197,667 |
) |
|
$ |
(154,766 |
) |
(1)Other segment expenses are comprised of general and administrative expenses, excluding share-based compensation expense, which is shown separately. |